Download Cardiovascular toxicity of local anesthetics

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Quantium Medical Cardiac Output wikipedia , lookup

Baker Heart and Diabetes Institute wikipedia , lookup

Myocardial infarction wikipedia , lookup

Saturated fat and cardiovascular disease wikipedia , lookup

Cardiovascular disease wikipedia , lookup

Transcript
Editor: Dean F. Connors, MD, PhD
Author: Ehab Morcos, MD
(2003-2004)
CARDIOVASCULAR TOXICITY OF
LOCAL ANESTHETICS
For the Boards…
PHARMACOLOGY
CARDIOVASCULAR TOXICITY OF LOCAL ANESTHETICS
Ehab Morcos, MD (2003-2004)
In general, much greater doses of local anesthetics are required to produce cardiovascular (CV)
toxicity than CNS toxicity. Similar to CNS toxicity, potency for CV toxicity reflects the anesthetic potency
of the agent. Recent attention has focused on the apparently exceptional cardiotoxicity of the more potent,
more lipid-soluble agents (bupivacaine, levo-bupivacaine, etidocaine, ropivacaine). These agents appear to
have a different sequence of CV toxicity than less potent agents. For example, increasing doses of lidocaine
leads to hypotension, bradycardia, and hypoxia, whereas bupivacaine often results in sudden cardiovascular
collapse due to ventricular dysrhythmias that are resistant to resuscitation. Subsequent studies have
identified multiple mechanisms in the CNS and CV system for increased cardiotoxicity from potent local
anesthetics.
Cardiovascular toxicity mediated at the CNS:
It has been demonstrated that the central and peripheral nervous systems may be involved in the
increased cardiotoxicity with bupivacaine. The nucleus tractus solitarii in the medulla is an important
region for autonomic control of the cardiovascular system. Neural activity in the nucleus tractus solitarii of
rats is markedly diminished by intravenous doses of bupivacaine immediately prior to development of
hypotension. Furthermore, direct intracerebral injection of bupivacaine can elicit sudden dysrhythmias and
cardiovascular collapse.
Cardiovascular toxicity mediated at the heart:
The more potent local anesthetics appear to possess greater potential for direct cardiac
electrophysiologic toxicity. A previous study examining lidocaine, bupivacaine, and ropivacaine in rats has
demonstrated equivalent peak effects on myocardial contractility but much greater effects on
electrophysiology (prolongation of QRS) from bupivacaine and ropivacaine than lidocaine. Although all
local anesthetics block the cardiac conduction system via dose-dependent block of sodium channels, two
features of bupivacaine’s sodium channel blocking abilities may enhance its cardiotoxicity. First,
bupivacaine exhibits a much stronger binding affinity to resting and inactivated sodium channels than
lidocaine. Second, local anesthetics bind to sodium channels during systole and dissociate during diastole.
Furthermore, bupivacaine inhibits calcium channels, release of calcium from sacroplasmic reticulum, and
mitochondrial energy metabolism, thus multiple direct effects of bupivacaine on activity of the cardiac
myocyte may enhance the cardiotoxicity of bupivacaine. The multitude of different cardiac and neural
mechanisms of cardiotoxicity may in part explain the reported difficulties of resuscitation after
cardiovascular collapse from bupivacaine.
References:
1.
Clinical Anesthesia, Fourth edition, Paul G. Barash, Lippincott Williams and Wilkins, 2001, Page
460-462.
Ehab Morcos, MD
2003-2004